Mifepristone has limited activity to enhance the in vivo efficacy of docetaxel and enzalutamide against bone metastatic and castration-resistant prostate cancer

Yang Yang, Xin Li, Kenza Mamouni, Omer Kucuk, Daqing Wu

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Fingerprint

Dive into the research topics of 'Mifepristone has limited activity to enhance the in vivo efficacy of docetaxel and enzalutamide against bone metastatic and castration-resistant prostate cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences